Auro Laboratories fixed-asset purchases reach Rs 18.02 crore

Auro Laboratories Limited reported Rs 18.02 crore of fixed-asset purchases in the half year ended September 30, 2026, while cash and cash equivalents fell by Rs 37.13 lakh to Rs 99.55 lakh and property, plant and equipment increased by Rs 16.17 crore.

How much did Auro Laboratories spend on fixed assets?

Auro Laboratories reported Rs 18.02 crore under purchase of fixed assets in investing cash flows for the half year ended September 30, 2026. The same cash-flow statement separately listed Rs 14.48 crore as capital expenditure on fixed assets, including capital advances, and recorded net cash used in investing activities of Rs 3.62 crore.

The filing presents the Rs 14.48 crore capital-expenditure line and the Rs 18.02 crore purchase-of-fixed-assets line separately, with the latter shown as an outflow. It also recorded Rs 8.55 lakh of fixed deposits placed, interest received of Rs 9,000 and dividend received of Rs 1,000 within investing activities. Auro Laboratories did not provide a project-wise asset, supplier, facility or commissioning-date breakdown.

In the half year ended September 30, 2025, net cash used in investing activities was Rs 10.59 crore, compared with Rs 3.62 crore in H1 FY2027. The prior-period cash-flow statement included Rs 10.60 crore of capital expenditure on fixed assets, including capital advances, but no separate purchase-of-fixed-assets amount. The presentation therefore changed between the two reported half-years.

How did Auro Laboratories' non-current assets change?

Auro Laboratories' property, plant and equipment, or PPE, rose to Rs 91.36 crore at September 30, 2026 from Rs 75.18 crore at March 31, 2026. The Rs 16.17 crore increase occurred as capital work-in-progress of Rs 14.48 crore at the March year-end was no longer reported in the September balance sheet.

Total non-current assets increased by Rs 1.60 crore to Rs 91.91 crore, a much smaller rise than the PPE movement because capital work-in-progress was absent at September 30. Other non-current assets declined to Rs 55.08 lakh from Rs 64.51 lakh, while non-current investments rose to Rs 56,000 from Rs 54,000.

The balance-sheet movement is consistent with a change in the composition of non-current assets during the six months, but Auro Laboratories did not state why the capital work-in-progress line became nil. The company reported one operating segment, pharmaceuticals, and did not disclose whether the assets related to a particular product category or manufacturing activity.

What happened to Auro Laboratories' cash and working capital?

Auro Laboratories ended September 30, 2026 with cash and cash equivalents of Rs 99.55 lakh, compared with Rs 1.37 crore at March 31, 2026. Its cash-flow statement recorded a net decrease of Rs 37.13 lakh during H1 FY2027 and closing cash and cash equivalents of Rs 99.56 lakh.

Bank balances other than cash and cash equivalents rose to Rs 38.59 lakh from Rs 30.04 lakh over the same period. The cash-flow reconciliation listed total cash and cash equivalents of Rs 1.38 crore before deducting those Rs 38.59 lakh of balances not considered cash equivalents, resulting in Rs 99.55 lakh of net cash and cash equivalents.

Net cash from operating activities was Rs 6.31 crore in H1 FY2027, below Rs 9.29 crore in the half year ended September 30, 2025. Inventories absorbed Rs 2.70 crore and trade receivables absorbed Rs 3.14 crore in the current half, whereas the prior-year period showed a Rs 2.18 crore reduction in receivables and a Rs 4.85 crore inventory increase.

At September 30, inventories stood at Rs 16.24 crore, up from Rs 13.54 crore at March 31, while trade receivables rose to Rs 12.29 crore from Rs 9.15 crore. These two balances increased by Rs 5.85 crore in aggregate, while trade payables rose by Rs 3.48 crore to Rs 8.16 crore.

Did Auro Laboratories increase short-term borrowing?

Auro Laboratories' short-term borrowings increased to Rs 21.54 crore at September 30, 2026 from Rs 19.99 crore at March 31, 2026. The Rs 1.54 crore increase corresponds with Rs 1.54 crore of proceeds from other short-term borrowings reported in H1 FY2027 cash flows.

Non-current financial liabilities declined to Rs 41.47 crore from Rs 43.31 crore. The cash-flow statement recorded Rs 1.84 crore of repayment of long-term borrowings and no proceeds from long-term borrowings during the six months ended September 30, 2026.

Finance costs rose to Rs 2.76 crore in H1 FY2027 from Rs 1.24 crore in H1 FY2026. For the September 2026 quarter, finance cost was Rs 1.39 crore, compared with Rs 96.23 lakh in the September 2025 quarter. The results do not disclose interest rates, lenders, security, maturity schedules or the use of individual borrowings.

Current liabilities reached Rs 33.17 crore at September 30 from Rs 28.55 crore at March 31. Alongside higher short-term borrowings and trade payables, other current liabilities declined to Rs 3.36 crore from Rs 3.77 crore, while current tax liabilities were unchanged at Rs 11.64 lakh.

How did Auro Laboratories' earnings change during the asset expansion?

Auro Laboratories reported revenue from operations of Rs 22.71 crore for H1 FY2027, compared with Rs 11.61 crore in H1 FY2026. Profit after tax rose to Rs 2.22 crore from Rs 61.03 lakh, while profit before tax increased to Rs 3.00 crore from Rs 1.61 crore.

Depreciation and amortisation increased to Rs 1.85 crore in H1 FY2027 from Rs 92.49 lakh a year earlier. The increase coincided with the Rs 16.17 crore rise in PPE, although Auro Laboratories did not identify which assets were available for use during the period or specify their depreciation treatment.

Total assets were Rs 126.85 crore at September 30, 2026, compared with Rs 121.08 crore at March 31. Equity increased to Rs 48.59 crore from Rs 46.35 crore, including other equity of Rs 42.33 crore against Rs 40.12 crore at the previous year-end; paid-up share capital remained Rs 6.23 crore.

Conclusion

Auro Laboratories' first-half filing shows that a substantial fixed-asset movement coincided with a lower cash-equivalent balance, higher short-term borrowings and increased working-capital balances. PPE rose by Rs 16.17 crore as capital work-in-progress of Rs 14.48 crore was no longer reported, while the cash-flow statement separately recorded Rs 18.02 crore in fixed-asset purchases.

The filing does not disclose the projects behind the asset movements, their commissioning dates, or how the two fixed-asset cash-flow lines relate to each other. The next relevant disclosures would be any explanation of those matters and whether depreciation of Rs 1.85 crore, finance costs of Rs 2.76 crore, receivables of Rs 12.29 crore and short-term borrowings of Rs 21.54 crore continue to change.